Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FVIIa/FX prophylaxis for bleeding prevention in acquired hemophilia A
jRCT1041240142Recruiting
- Sponsor
- Matsushita Tadashi
- Start
- Oct 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of coagulation factor VIIa + factor X and emicizumab in acquired haemophilia (AH) (2 arms), sponsored by Matsushita Tadashi. Primary endpoint: Number of bleedings requiring treatment (annual bleed rate). Started Oct 2025; status: recruiting.
02
Drugs
coagulation factor VIIa + factor Xemicizumab
03
Conditions
acquired haemophilia (AH)
Beyond the preview
Go deeper on jRCT1041240142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041240142.